Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Braftovi + Mektovi (encorafenib / binimetinib by Year
Braftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — U.S. revenues ($M) ($M)
Pfizer Braftovi + Mektovi (encorafenib / binimetinib: $672M in FY2025, up 15.9% from a year earlier.
Where the FY2025 figure comes from
“|| Braftovi/Mektovi | 716 | 607 | 18% | 18% | 672 | 580 | 16% | 45 | 27 | 67% | 71%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Braftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — U.S. revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 672 | +15.9% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 580 | +24.7% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 465 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
Breakdown
What makes up braftovi + Mektovi (encorafenib / binimetinib
Cite this data
StockData. (2026). Pfizer Braftovi + Mektovi (encorafenib / binimetinib ($M), annual FY2023–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/braftovi-mektovi-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.